Effect of D1-like and D2-like receptor antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine self-administration in rats.
Katharine A Brennan, Caleb Carati, Rod A Lea, Paul S. Fitzmaurice, Susan Schenk
Behavioural Pharmacology December 2009 DOI: 10.1097/fbp.0b013e328333a28d (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical dose-response study Peer reviewed |
|---|---|
| Population | Rats self-administering MDMA or methamphetamine |
| Interventions | Eticlopride SCH23390 MDMA Methamphetamine |
| Dose | Eticlopride 0.0, 0.0125, 0.025 or 0.05 mg/kg intraperitoneal; SCH23390 0.0, 0.01 or 0.02 mg/kg subcutaneous; MDMA 0.5, 1.0 and 2.0 mg/kg/infusion; methamphetamine 0.05, 0.1 and 0.2 mg/kg/infusion |
| Topics | MDMA |
| Key points | Eticlopride increased responding maintained by most MDMA doses but did not alter methamphetamine self-administration, while SCH23390 decreased responding for most methamphetamine doses. The authors suggest both D1-like and D2-like receptors contribute to MDMA self-administration, whereas methamphetamine self-administration is more sensitive to D1-like receptor blockade. |
Abstract
It has been suggested that activation of dopamine D1-like and D2-like receptors contribute equally to the maintenance of drug self-administration. This study compared the contribution of these receptor subtypes to 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine (MA) self-administration. Effects of pretreatment with the D2-like receptor antagonist, eticlopride (0.0, 0.0125, 0.025 or 0.05 mg/kg, intraperitoneal), on responding maintained by several doses of MDMA (0.5, 1.0 and 2.0 mg/kg/infusion) and MA (0.05, 0.1 and 0.2 mg/kg/infusion) were determined. As we have published data showing the effects of the D1-like receptor antagonist, SCH23390 (0.0, 0.01 or 0.02 mg/kg, subcutaneous), on MDMA self-administration, effects of this dose range on the MA dose-response curve were determined. In our previous study, 0.02 mg/kg SCH23390 produced a rightward shift in the MDMA dose response curve, whereas in the present results, this dose decreased responding maintained by most doses of MA. Eticlopride increased the responding maintained by most doses of MDMA but failed to alter MA self-administration. The present results suggest that both D1-like and D2-like receptors contribute to the maintenance of MDMA self-administration, whereas MA self-administration was more sensitive to D1-like receptor blockade.
Comparable studies
Other preclinical and animal studies on MDMA, most cited first.
Citations in the library
Cited by 22
- Distinct neural mechanisms for the prosocial and rewarding properties of MDMA Science Translational Medicine December 11, 2019
- Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology July 24, 2023
- Acquisition of MDMA self‐administration: pharmacokinetic factors and MDMA‐induced serotonin release Addiction Biology June 14, 2013
- Use and abuse of dissociative and psychedelic drugs in adolescence Pharmacology, Biochemistry, and Behavior January 27, 2021
- Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse Journal of Neurochemistry March 12, 2021
and 17 more in the library
Cites 3
- MDMA self‐administration in rats: acquisition, progressive ratio responding and serotonin transporter binding European Journal of Neuroscience November 16, 2007
- Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience March 27, 2008
- The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacological Reviews September 2003